Materials Healthcare Sector

Gossamer Bio

Market Cap: US$261.3m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

Health Catalyst

Market Cap: US$260.3m

Provides data and analytics technology and services to healthcare organizations in the United States.

Inozyme Pharma

Market Cap: US$255.0m

A clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.

Vanda Pharmaceuticals

Market Cap: US$254.6m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Palvella Therapeutics

Market Cap: US$254.0m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Healwell AI

Market Cap: CA$351.5m

A healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.

Neurogene

Market Cap: US$249.4m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Monte Rosa Therapeutics

Market Cap: US$246.7m

A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

Tristel

Market Cap: UK£183.7m

Develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally.

Verano Holdings

Market Cap: CA$341.7m

Operates as a vertically integrated multi-state cannabis operator in the United States.

Allogene Therapeutics

Market Cap: US$242.8m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Silence Therapeutics

Market Cap: US$242.8m

A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

Rezolute

Market Cap: US$242.7m

A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Ocugen

Market Cap: US$242.4m

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.

Aardvark Therapeutics

Market Cap: US$241.3m

A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Tenax Therapeutics

Market Cap: US$240.9m

A clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

Cartesian Therapeutics

Market Cap: US$240.9m

A clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

Atea Pharmaceuticals

Market Cap: US$240.5m

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.

MaxCyte

Market Cap: UK£178.1m

A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

Cerus

Market Cap: US$239.0m

Operates as a biomedical products company.

Lifecore Biomedical

Market Cap: US$238.8m

Operates as an integrated contract development and manufacturing organization in the United States.

ZimVie

Market Cap: US$237.9m

Develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide.

Nuvectis Pharma

Market Cap: US$237.5m

A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Jade Biosciences

Market Cap: US$235.3m

Operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Animalcare Group

Market Cap: UK£175.2m

Develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets.

Oncology Institute

Market Cap: US$234.8m

An oncology company, provides various medical oncology services in the United States.

Third Harmonic Bio

Market Cap: US$233.8m

A biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.

Creative Medical Technology Holdings

Market Cap: US$232.3m

A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

AirSculpt Technologies

Market Cap: US$230.1m

Focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom.

Acelyrin

Market Cap: US$229.2m

A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Tactile Systems Technology

Market Cap: US$229.0m

A medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.

Fennec Pharmaceuticals

Market Cap: US$229.0m

Operates as a commercial stage biopharmaceutical company in the United States.

Optima Health

Market Cap: UK£170.0m

Provides occupational health and wellbeing services for the public and private sectors in the United Kingdom.

Amarin

Market Cap: US$227.4m

A pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.

Mayne Pharma Group

Market Cap: AU$353.4m

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Foghorn Therapeutics

Market Cap: US$226.3m

A clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.